Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: Role of brain innate immune system

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 3, 2016, Pages 329-336

  Leszek, Jerzy ^a   Barreto, George E ^b,c   Gąsiorowski, Kazimierz ^a   Koutsouraki, Euphrosyni ^d   Ávila Rodrigues, Marco ^b   Aliev, Gjumrakch ^e,f,g  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e GALLY International Biomedical Research Consulting LLC   (United States)

^f University of Atlanta   (United States)

^g INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

Microglia; Neurodegenerative disorders; Neuroinflammation; Oxidative stress; Toll like receptors

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD200 ANTIGEN; CD200 RECEPTOR; CD36 ANTIGEN; CD47 ANTIGEN; CHAPERONIN 60; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 6; CYTOKINE;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DNA POLYMORPHISM; GENE MUTATION; HUMAN; INNATE IMMUNITY; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DEGENERATIVE DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICROGLIA; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84961577153     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160202125914     Document Type: Article

References (102)

1. Rock RB, et al., Role of Microglia in Central Nervous System Infections. Clinical Microbiology Reviews 2004; 17(4): 942-964.
2. Zwain, I.H. and S.S.C. Yen, Neurosteroidogenesis in Astrocytes, Oligodendrocytes, and Neurons of Cerebral Cortex of Rat Brain. Endocrinology 1999; 140(8): 3843-3852.
3. Bélanger M, I. Allaman, and P.J. Magistretti, Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic Cooperation. Cell Metabolism 2011; 14(6): 724-738.
4. Liazoghli D, et al., Substrate Micropatterning as a New in Vitro Cell Culture System to Study Myelination. ACS Chemical Neuroscience 2012; 3(2): 90-95.
5. Bitzer-Quintero, O.K. and I. González-Burgos, Immune System in the Brain: A Modulatory Role on Dendritic Spine Morphophysiology? Neural Plasticity 2012; 2012.
6. Ramesh G, A.G. MacLean, and M.T. Philipp, Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain. Mediators of Inflammation 2013; 2013.
7. Xie A, et al., Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease. BioMed Research International 2014; 2014.
8. Lau FC, B. Shukitt-Hale, and J.A. Joseph, Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell Biochem 2007; 42: 299-318.
9. Peila, R. and L.J. Launer, Inflammation and dementia: epidemiologic evidence. Acta Neurol Scand Suppl 2006; 185: 102-6.
10. Abstracts The Israel Society for Neuroscience 18th Annual Meeting. Journal of Molecular Neuroscience 2009; 39(1): 1-132.
11. Schwartz, M. and R. Shechter, Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 2010; 6(7): 405-10.
12. Schwartz, M. and Y. Ziv, Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol 2008; 29(5): 211-9.
13. Lucin, K.M. and T. Wyss-Coray, Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009; 64(1): 110-22.
14. Ashraf GM, et al., Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS & neurological disorders drug targets 2014; 13(7): 1280-1293.
15. Mirza Z, et al., Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS & neurological disorders drug targets 2014; 13(2): 213-225.
16. Guo C, et al., Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res 2013; 8(21): 2003-14.
17. Bredesen DE, R.V. Rao, and P. Mehlen, Cell death in the nervous system. Nature 2006; 443(7113): 796-802.
18. Rubinsztein DC, The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443(7113): 780-6.
19. Rivest S, Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9(6): 429-39.
20. Crutcher KA, et al., Debate: "is increasing neuroinflammation beneficial for neural repair?". J Neuroimmune Pharmacol 2006; 1(3): 195-211.
21. Popovich, P.G. and E.E. Longbrake, Can the immune system be harnessed to repair the CNS? Nat Rev Neurosci 2008; 9(6): 481-93.
22. Tansey MG, M.K. McCoy, and T.C. Frank-Cannon, Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208(1): 1-25.
23. Lull, M.E. and M.L. Block, Microglial Activation & Chronic Neurodegeneration. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2010; 7(4): 354-365.
24. Posada-Duque RA, G.E. Barreto, and G.P. Cardona-Gomez, Protection after stroke: cellular effectors of neurovascular unit integrity. Front Cell Neurosci 2014; 8: 231.
25. Harris RA, Spatial, Temporal, and Functional Aspects of Macrophages during "The Good, the Bad, and the Ugly" Phases of Inflammation. Front Immunol 2014; 5: 612.
26. Block, M.L. and J.S. Hong, Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76(2): 77-98.
27. McGeer, E.G. and P.L. McGeer, The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007; 21(10): 789-97.
28. Mrak, R.E. and W.S. Griffin, Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005; 26(3): 349-54.
29. Cabezas R, et al., Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front Cell Neurosci 2014; 8: 211.
30. Booy E, et al., The Immune System, Involvement in Neurodegenerative Diseases, Ageing and Cancer. Current Medicinal Chemistry anti-inflammatory & anti-allergy agents 2013; 4(4): 349-352.
31. Frank-Cannon TC, et al., Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47.
32. Tansey, M.G. and T. Wyss-Coray, Cytokines in CNS Inflammation and Disease, in Central Nervous System Diseases and Inflammation, T.E.C., M. Lane, C. Bergmann, and T. Wyss-Coray, Editors. 2008, Springer: New York. p. 59-106.
33. Barreto GE, M. Santos-Galindo, and L.M. Garcia-Segura, Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury. Front Aging Neurosci 2014; 6: 132.
34. Chen Y, et al., Targeting microglial activation in stroke therapy: pharmacological tools and gender effects. Curr Med Chem 2014; 21(19): 2146-55.
35. Lee EJ, et al., Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-alpha activation. J Immunol 2014; 193(5): 2384-93.
36. Liu P, et al., MicroRNA-424 Protects Against Focal Cerebral Ischemia and Reperfusion Injury in Mice by Suppressing Oxidative Stress. Stroke 2014;
37. Stoica BA, et al., PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. J Neurotrauma 2014; 31(8): 758-72.
38. Beutner C, et al., Unique transcriptome signature of mouse microglia. Glia 2013; 61(9): 1429-42.
39. Miklossy J, et al., Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006; 197(2): 275-83.
40. Kurpius D, et al., Early activation, motility, and homing of neonatal microglia to injured neurons does not require protein synthesis. Glia 2006; 54(1): 58-70.
41. Benakis C, C. Bonny, and L. Hirt, JNK inhibition and inflammation after cerebral ischemia. Brain Behav Immun 2010; 24(5): 800-11.
42. Chio CC, M.T. Lin, and C.P. Chang, Contribution of Microglial Activation as Compelling Target for the Treatment of Acute Trauatic Brain Injury. Curr Med Chem 2014;
43. Schmid CD, et al., Differential gene expression in LPS/IFNgamma activated microglia and macrophages: in vitro versus in vivo. J Neurochem 2009; 109 Suppl 1: 117-25.
44. Xiong X, et al., Increased brain injury and worsened neurological outcome in interleukin-4 knockout mice after transient focal cerebral ischemia. Stroke 2011; 42(7): 2026-32.
45. Barreto GE, et al., Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res 2011; 71(2): 107-13.
46. Cabezas R, et al., Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci Res 2012; 74(2): 80-90.
47. Drose S, U. Brandt, and I. Wittig, Mitochondrial respiratory chain complexes as sources and targets of thiol-based redox-regulation. Biochim Biophys Acta 2014; 1844(8): 1344-54.
48. Babot M, et al., Characterisation of the active/de-active transition of mitochondrial complex I. Biochim Biophys Acta 2014; 1837(7): 1083-92.
49. Scheibye-Knudsen M, et al., Protecting the mitochondrial powerhouse. Trends Cell Biol 2014;
50. Luque-Contreras D, et al., Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxid Med Cell Longev 2014; 2014: 497802.
51. Meraz-Rios MA, et al., Early onset Alzheimer's disease and oxidative stress. Oxid Med Cell Longev 2014; 2014: 375968.
52. de la Monte, S.M. and M. Tong, Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 2014; 88(4): 548-59.
53. Moreira PI, et al., The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mech Ageing Dev 2006; 127(6): 501-6.
54. Albarracin SL, et al., Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 2012; 15(1): 1-9.
55. Castellani RJ, et al., Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen 2006; 21(2): 126-30.
56. Castellani RJ, et al., Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 2006; 111(6): 503-9.
57. Forman MS, et al., Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 2007; 68(10): 757-63.
58. Pratico D, Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 2002; 63(4): 563-7.
59. Smith MA, et al., Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002; 33(9): 1194-9.
60. Sutachan JJ, et al., Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr Neurosci 2012; 15(3): 120-6.
61. Aliev G, et al., Implication of Oxidative Stress-Induced Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegeneration and Cancer, in Systems Biology of Free Radicals and Antioxidants, I. Laher, Editor. 2011, Springer Berlin Heidelberg. p. 2325-2347.
62. Aliev G, et al., The Three-Vessel Occlusion as a Model of Vascular Dementia – Oxidative Stress and Mitochondrial Failure as an Indicator of Brain Hypoperfusion, in Systems Biology of Free Radicals and Antioxidants, I. Laher, Editor. 2009, Springer Berlin Heidelberg. p. 2023-2032.
63. Cabezas R, et al., PDGF-BB Protects Mitochondria from Rotenone in T98G Cells. Neurotox Res 2014;
64. Ahmad A, et al., Brain region specific monoamine and oxidative changes during restraint stress. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 2012; 39(3): 311-318.
65. Ahmad A, et al., Novel Ocimum sanctum compounds modulate stress response: Role of CRF, POMC, GR and HSP-70 in the hypothalamus and pituitary of rats. Medicinal Plants - International Journal of Phytomedicines and Related Industries 2013; 5(4).
66. Ahmad A, et al., Novel Ocimumoside A and B as anti-stress agents: modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2012; 19(7): 639-647.
67. Chao Y, S.C. Wong, and E.K. Tan, Evidence of Inflammatory System Involvement in Parkinsons Disease. BioMed Research International 2014; 2014.
68. Landskron G, et al., Chronic Inflammation and Cytokines in the Tumor Microenvironment. Journal of Immunology Research 2014; 2014.
69. Avila MF, et al., Structural insights from GRP78-NF-kappaB binding interactions: a computational approach to understand a possible neuroprotective pathway in brain injuries. J Theor Biol 2014; 345: 43-51.
70. Okamoto T, NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006; 6(4): 359-72.
71. Walter S, et al., Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007; 20(6): 947-56.
72. Del Bo R, et al., Reciprocal control of inflammatory cytokines, IL- 1 and IL-6, and beta-amyloid production in cultures. Neurosci Lett 1995; 188(1): 70-4.
73. Goldgaber D, et al., Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 1989; 86(19): 7606-10.
74. Misonou H, M. Morishima-Kawashima, and Y. Ihara, Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 2000; 39(23): 6951-9.
75. Aliev G, et al., Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014; 21(19):2208-17.
76. Yan SD, et al., Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995; 1(7): 693-9.
77. Wang X, et al., Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 2014; 1842(8): 1240-7.
78. Lehnardt S, Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010; 58(3): 253-63.
79. Okun E, et al., Toll-like receptors in neurodegeneration. Brain Res Rev 2009; 59(2): 278-92.
80. Vontell R, et al., Toll-like receptor 3 expression in glia and neurons alters in response to white matter injury in preterm infants. Dev Neurosci 2013; 35(2-3): 130-9.
81. Wang Y, H.J. He, and W. Ouyang, Increased expression of toll-like receptor 4 on neurons after surgery in aged rats. CNS Neurosci Ther 2013; 19(5): 358-60.
82. Kawai, T. and S. Akira, Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143: 1-20.
83. Dai XJ, et al., Activation of BV2 microglia by lipopolysaccharide triggers an inflammatory reaction in PC12 cell apoptosis through a toll-like receptor 4-dependent pathway. Cell Stress Chaperones 2014;
84. Lehnardt S, et al., A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J Neurosci 2008; 28(10): 2320-31.
85. Zhang Z, et al., Immunolocalization of Toll-like receptors 2 and 4 as well as their endogenous ligand, heat shock protein 70, in rat traumatic brain injury. Neuroimmunomodulation 2012; 19(1): 10-9.
86. Letiembre M, et al., Innate immune receptor expression in normal brain aging. Neuroscience 2007; 146(1): 248-54.
87. Christensen LB, et al., Age-related differences in neuroinflammatory responses associated with a distinct profile of regulatory markers on neonatal microglia. J Neuroinflammation 2014; 11: 70.
88. Qian F, et al., Reduced bioenergetics and toll-like receptor 1 function in human polymorphonuclear leukocytes in aging. Aging (Albany NY) 2014; 6(2): 131-9.
89. Harry GJ, Microglia during development and aging. Pharmacol Ther 2013; 139(3): 313-26.
90. Arroyo DS, et al., Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 2011; 11(10): 1415-21.
91. Bamberger ME, et al., A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003; 23(7): 2665-74.
92. Reed-Geaghan EG, et al., CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 2009; 29(38): 11982-92.
93. Tang SC, et al., Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 2008; 213(1): 114-21.
94. Trotta T, et al., Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 2014; 268(1-2): 1-12.
95. Chen YC, et al., Sequence variants of toll like receptor 4 and lateonset Alzheimer's disease. PLoS One 2012; 7(12): e50771.
96. Song M, et al., TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 2011; 8: 92.
97. Minoretti P, et al., Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett 2006; 391(3): 147-9.
98. Tang SC, et al., Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007; 104(34): 13798-803.
99. Caso JR, et al., Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115(12): 1599-608.
100. Adelson JD, et al., Neuroprotection from stroke in the absence of MHCI or PirB. Neuron 2012; 73(6): 1100-7.
101. Boulanger LM, Immune proteins in brain development and synaptic plasticity. Neuron 2009; 64(1): 93-109.
102. Stevens B, et al., The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131(6): 1164-78.